TY  - JOUR

T1  - Phase 2 study of the efficacy and safety of erdafitinib in patients (pts) with intermediate-risk non–muscle-invasive bladder cancer (IR-NMIBC) with <i>FGFR3/2</i> alterations (alt) in THOR-2: Cohort 3 interim analysis.

JO  - Journal of Clinical Oncology

UR  - http://dx.doi.org/10.1200/jco.2023.41.6_suppl.504

PY  - 2023/02/20

AU  - Daneshmand S

AU  - Zaucha R

AU  - Gartrell BA

AU  - Lotan Y

AU  - Hussain SA

AU  - Lee EK

AU  - Procopio G

AU  - Galanternik F

AU  - Naini V

AU  - Carcione J

AU  - Triantos S et al

ED  - 

DO  - DOI: 10.1200/jco.2023.41.6_suppl.504

PB  - American Society of Clinical Oncology (ASCO)

VL  - 41

IS  - 6_suppl

SP  - 504

EP  - 504

Y2  - 2024/12/22

ER  -